{
  "docId": "019de072-75de-708e-aad9-55788df6c953",
  "docSlug": "5188528054c3088b6a98b04815eb3ce3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 40,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a split layout: left side details R&D strategy (LCM vs NME), right side provides a timeline of upcoming regulatory/clinical milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-75de-708e-aad9-55788df6c953/26",
  "deckHref": "/decks/019de072-75de-708e-aad9-55788df6c953",
  "deckJsonHref": "/decks/019de072-75de-708e-aad9-55788df6c953.json",
  "deckAnchorHref": "/decks/019de072-75de-708e-aad9-55788df6c953#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "LCM = lifecycle management; NME = new molecular entity; NMOSD = neuromyelitis optica spectrum disorder; NF1-PN = neurofibromatosis type 1 with plexiform neurofibromas; gMG = generalised myasthenia gravis; PNH = paroxysmal nocturnal haemoglobinuria; aHUS = atypical haemolytic uraemic syndrome; GBS = guillian-barre syndrome; PNH with EVH = paroxysmal nocturnal haemoglobinuria with extravascular haemolysis; s.c. = subcutaneous; reg. = regulatory.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "909bfb94-18d4-4a65-9716-b4a55926f001",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.03,
        "y": 0.58
      },
      "kind": "list",
      "text": "Diverse product offering addresses full spectrum of patient needs; Opportunity to expand into broader patient populations with differentiated pricing strategy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "479ad41e-033b-4c3e-8b8a-60512e21ca20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.35,
        "y": 0.58
      },
      "kind": "list",
      "text": "C5 mini-body and anti-properdin low-volume, subcutaneous with potential in numerous diseases; Oral Factor D potential best-in-class",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a837cdf7-bb63-41c6-a294-314bdb793c54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.68,
        "y": 0.25
      },
      "kind": "list",
      "text": "Key upcoming news flow 2022-2023",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e3cbeae-49fc-42a4-83e2-5a5b6a4d8e50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Innovative LCM and NME programs reinforce complement leadership",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6533373f-c8aa-47b6-acc7-2b0991816011",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Rare Disease: Q1 2022 R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1249963-f091-4068-a264-358a71ebb112",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "c69af593-d5c1-4990-aa6d-9ee6b0b468ea",
      "evidence": "list/bullet: Diverse product offering addresses full spectrum of patient needs; Opportunity to expand into broader patient populations with differentiated pricing strategy",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "8bc17c31-0ed5-406d-b5f0-c579676c355d",
      "evidence": "Key upcoming news flow section",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}